A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）

The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and <18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.

Start Date29 Dec 2025

Sponsor / Collaborator

Innovent Biologics (Suzhou) Co. Ltd.

NCT07135141

/ Not yet recruitingNot ApplicableIIT

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity:A Multicenter, Randomized, Double-Blind, Placebo-Controlled Superiority Trial

The SMART study is a 96-week, multicenter, randomized, double-blind, placebo-controlled superiority clinical trial. A total of 256 severe obesity patients are randomized 1:1 to either receive the bariatric surgery plus GCG/GLP-1 dual receptor agonist group (receiving sleeve gastrectomy followed by subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the bariatric surgery plus placebo group (receiving matched procedure plus placebo injections). The primary objective is to evaluate the potential enhancing weight reduction effects of the combination therapy with bariatric surgery and mazdutide measured by the percentage change of excess weight loss.

Start Date30 Sep 2025

Sponsor / Collaborator

Beijing Friendship Hospital

NCT07083154

/ RecruitingPhase 3IIT

Efficacy, Safety, and Tolerability of a GLP-1/GCG Dual Receptor Agonist in Type 2 Diabetes With Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial

The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the placebo group (receiving matched placebo injections). The primary objective is to evaluate the potential disease-modifying effects of mazdutide on cognitive dysfunction in type 2 diabetes.

Start Date27 Sep 2025

Sponsor / Collaborator

Shanghai First People's Hospital

[+4]

100 Clinical Results associated with Mazdutide

100 Translational Medicine associated with Mazdutide

100 Patents (Medical) associated with Mazdutide

Literatures (Medical) associated with Mazdutide

01 Feb 2026·Lancet Diabetes & Endocrinology

Obesity in China: current progress and future prospects

Review

Author: Fang, Zhong-Ze ; Zhang, Lingli ; Pan, Xiong-Fei ; Pan, An

The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences. In this Personal View, we critically examine recent advances and identify current and emerging challenges in obesity across public health and policy, clinical research, and practice. National policy frameworks, technical health and nutrition guidelines, and multisectoral collaboration have elevated obesity on the public agenda. Evidence supporting lifestyle interventions and medications for obesity continues to accumulate. Since 2021, five additional GLP-1 receptor agonists (including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide) have been approved in China for weight management, broadening therapeutic choices and initiating a transformation in obesity care. Nevertheless, several key challenges remain which can undermine the sustained impact of the progress. These include limitations in existing diagnostic criteria for obesity which captures phenotypic and cardiometabolic heterogeneity; limited availability of quantifiable, actionable, and accountable national targets which weakens governance and evaluation; and a scarcity of evidence-based algorithms for obesity pharmacotherapy, which risks over-reliance on medication and diverts attention from socioeconomic, environmental, and behavioural determinants. We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support.

01 Jan 2026·Contemporary Clinical Trials

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

Article

Author: Li, Shu ; Zhou, Runze ; Li, Yunfeng ; Cai, Hanqing ; Luo, Yingying ; Qian, Lei ; Li, Li ; Ji, Linong ; Qiu, Wei ; Shi, Bimin ; Guo, Qun ; Pei, Lijuan ; Jiang, Hongwei ; Zhang, Han Han ; Wang, Haifang ; Deng, Huan

BACKGROUND:

Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management strategies in the treatment of T2D and obesity. Glucagon receptor-based co-agonists, such as mazdutide, represent a promising therapeutic class with the potential for enhanced weight loss compared to current standards of care. However, robust clinical evidence for these agents in populations with T2D and obesity is still lacking. The DREAMS-3 trial is designed to address this gap by directly comparing the efficacy and safety of mazdutide against semaglutide, a widely used GLP-1 receptor agonist, in Chinese adults with T2D and obesity. The results will provide crucial evidence to inform clinical decision-making for this large patient population.

METHODS:

DREAMS-3 is a randomized, open-label phase 3 trial. Obese Participants (BMI ≥ 28 kg/m²) diagnosed with T2D (≤ 10 years) who had inadequate glycemic control after diet and exercise alone with/without metformin were randomized in a 1:1 ratio to receive mazdutide 6 mg or semaglutide 1 mg once weekly in the 32-week active-controlled treatment period, followed with a 24-week extension period. The primary endpoint is the proportion of participants achieving glycated hemoglobin <7.0 % and weight reduction of ≥10 % at week 32.

RESULTS:

A total of 349 participants were enrolled and randomized, the overall mean age was 42.4 years, 44.7 % of participants were male. The mean baseline duration of T2D was 1.8 years, and 39.5 % of participants were on metformin. The mean glycated hemoglobin was 8.0 %, body weight was 90.5 kg, BMI was 33.0 kg/m². Most participants had at least one comorbidity. The prevalence of some comorbidities (such as metabolic associated fatty liver disease, gout/hyperuricemia) showed strong association of BMI.

CONCLUSION:

DERAMS-3 is the first head-to-head trial to compare the efficacy and safety of mazdutide versus semaglutide in Chinese adults with T2D and obesity, with an expected completion date in early 2026.

01 Jan 2026·PHARMACOLOGICAL RESEARCH

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes

Review

Author: Hardaway, J Andrew ; Habegger, Kirk ; Elmendorf, Andrew J ; Flak, Jonathan N ; Kim, Il-Man ; Yousefian, Mostafa

The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation of treatment, the amount of which can depend on the treatment and patient, iterative advancements may improve weight loss durability in the long term. In this review, we discuss the development of glucagon like peptide-1 receptor (GLP-1R) agonists and GLP-1R/ glucose-dependent insulinotropic polypeptide receptor (GIPR) co-agonists, and how future generations will leverage this strategy. We focus our review on glucagon receptor (GCGR) agonism, which has recently been combined with both GLP-1R and GLP-1R/GIPR agonism to generate dual (e.g. survodutide, cotatutide, mazdutide, etc) and triple agonists (e.g. retatrutide, etc) for improved body weight loss via energy expenditure stimulation. We rely on largely pre-clinical evidence for action because clinical data is extremely limited for GCGR agonism. Herein, we review mechanisms by which glucagon receptor agonists act to increase energy expenditure. Finally, we discuss future improvements to incretin-based therapeutics, and how they can include strategies that target the GCGR. The purpose of this review is to discuss mechanisms by which GCGR agonism can reduce body weight and put them in the context of the combination with incretin receptor agonists. Mechanistic data has only currently been evaluated in preclinical rodent models and evidence for similar processes in humans is limited. We also provide perspectives about how treatments can improve for future advancement of obesity treatment.

News (Medical) associated with Mazdutide

12 Dec 2025

·endpoints.news

Innovent’s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor

Plus, news about BioCryst, Cycle Pharma, Applied Therapeutics, Contineum Therapeutics, Juncell Therapeutics, Cosette and Mayne Pharma: 📊 Innovent’s mazdutide shows early promise in adolescents : The injected GLP-1/glucagon agonist allowed body weight and BMI reductions of up to 9.9% and 11%, respectively, in patients with obesity at three months. The data came from a China-based Phase 1b trial in patients aged 12 to 17, and were statistically significantly better than the 1.2% and 1.7% respective weight and BMI reductions in the placebo group. Innovent said Thursday that an approval trial in adolescent obesity would begin “soon.” Mazdutide is sold in China as Xinermei, but only for adults, and no weight-loss drugs are specifically approved for children and adolescents in China. It is licensed to Eli Lilly for Western markets. — Elizabeth Cairns 🏔️ Everest Medicines makes a deal: Everest is paying $29 million upfront to fellow Chinese biotech Hasten Biopharmaceutical for the Greater China rights to develop the PCSK9 inhibitor lerodalcibep, which was developed by US-based company LIB Therapeutics. Hasten could get up to $30 million in development and regulatory biobucks and up to $280 million in sales milestones. — Kyle LaHucik ➕ FDA expands use of BioCryst drug to kids ages 2 and up: BioCryst said Friday that the FDA greenlit the use of an oral pellet version of its hereditary angioedema drug Orladeyo to kids aged 2 and up to prevent attacks associated with the disease. The therapy was previously approved for patients 12 and older. — Lei Lei Wu 🤝 Cycle Pharma plans to buy Applied Therapeutics: The private biotech plans to buy the Nasdaq-listed rare disease drug developer for 8 cents per share $APLT and up to 40 cents per share in a series of contingent-value rights. Applied said last month it would pursue strategic alternatives . Its drug candidate govorestat was rejected by the FDA last year. Cycle tried buying Vanda Pharmaceuticals last year but was rejected . — Kyle LaHucik 💰 Contineum Therapeutics raises $90M in stock sale: The I&I and neuroscience drug developer priced its public offering at $90 million after initially announcing plans for a $75 million offering. The stock sale comes after Contineum in November said a Phase 2 multiple sclerosis trial failed, though Wall Street analysts said the news was not catastrophic for the San Diego biotech. — Lei Lei Wu ⬆️ Another biotech eyes Hong Kong listing: Juncell Therapeutics filed for an IPO on the industry’s hottest stock exchange this year. Juncell is working on multiple cancer treatments, including a tumor-infiltrating lymphocyte (TIL) candidate that will be filed for approval next year. — Kyle LaHucik 🛑 Cosette and Mayne Pharma deal ends: The companies terminated their $387 million M&A deal this week after Australia’s government said last month it would block the transaction. — Kyle LaHucik Editor’s note: This story was updated to clarify that the Orladeyo approval was for the pellet version of the drug.

Drug ApprovalPhase 1Phase 2IPO

10 Dec 2025

·www.prnewswire.com

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 1 clinical trial of IBI3011, an anti-human Interleukin 1 receptor accessory protein (IL-1RAP) monoclonal antibody developed by Innovent. This study is a single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 for the first-in-human administration, so as to support the subsequent clinical development of IBI3011. A total of 40 healthy volunteers and 24 patients with gout flares are planned to be enrolled. With economic development and rising living standards, the number of gout patients in China is increasing. By 2019, the estimated number of patients had exceeded 3 million.[1],[2] When serum uric acid rises above its saturation point, urate crystals can deposit in joints, triggering local inflammation and tissue damage and causing gout flares.[3] Recurrent flares can lead to joint destruction and functional impairment, limiting patients' social roles and seriously reducing quality of life. At present, first-line pharmacologic treatments for gout flare mainly consist of nonsteroidal anti-inflammatory drugs and colchicine, to which certain patients have contraindications or cannot tolerate, lacking targeted therapies. Second-line therapies as glucocorticoids are also associated with numerous adverse effects. In addition, only one IL‑1β–targeted agent has been approved in China for the treatment of gout flare, and there remains a large unmet need in clinical practice. IL-1RAP, a member of the IL-1 family, serves as a co-receptor that forms receptor complexes with IL-1R1, ST2, and IL-36R and mediates downstream signaling pathways triggered by IL1α/β, IL33 and IL36, respectively. These cytokines are implicated in a broad spectrum of autoimmune and inflammatory diseases including acute gouty arthritis, hidradenitis suppurativa, etc. Compared with anti‑IL‑1β antibodies, targeting IL‑1RAP can simultaneously block multiple IL‑1 family inflammatory pathways, with the potential to rapidly control inflammation, relieve gout symptoms, and enable earlier initiation of urate‑lowering therapy. IBI3011 is the first anti-IL ‑ 1RAP monoclonal antibody in China aimed to address inflammatory and autoimmune diseases. Preclinical data show that IBI3011 can significantly suppress gout flares in models of acute gouty arthritis, highlighting its clinical potential for the treatment of gout flares. In this therapeutic area, Innovent plans to initiate a Phase 3 trial of IBI128 (tigulixostat) in gout patients with hyperuricemia. Previously, the Phase 2 clinical results of IBI128 were presented at APLAR 2025 showing strong efficacy in reducing serum uric acid in patients with gout. On top of that, IBI3011 has the potential to further suppress gout flares, complementing tigulixostat's uric acid-lowering effect to provide a more comprehensive treatment approach for patients with hyperuricemia and gout. Additionally, Mazdutide could also provide the benefit of reducing blood uric acid in the obesity population. Together, these assets provide more personalized treatment options for patients with gout and hyperuricemia. With IBI3011 now entering the clinical stage, Innovent will further strengthen its pipeline in metabolic and autoimmune diseases. Dr. Lei Qian, Chief R&D Officer of General Biomedicine of Innovent Biologics, stated, "I am very pleased that the first participant has been dosed in the Phase 1 clinical study of IBI3011, and I look forward to its result supporting the development of treatments for gout flares and other indications. Innovent Biologics' general biomedicine pipeline reflects a well-structured, echeloned and matrix-like strategy across the fields of cardiovascular and metabolic diseases (CVM), autoimmune diseases, and ophthalmology. For gout, a metabolic and immune-related condition, IB3011 complements the promising Phase 2 clinical results of IBI128 (tigulixostat), which demonstrated excellent efficacy in targeting XOI and is now advancing to Phase 3. By focusing on next-generation global innovations, Innovent is accelerating the development of high-potential molecules and the synergy of these products is expected to bring more innovative therapies that improve the quality of life to patients around the world." About IBI3011 IBI3011 is a monoclonal antibody targeting IL‑1RAP. As a co‑receptor, IL‑1RAP forms receptor complex with IL‑1R1, ST2, and IL‑36R, hence mediating activation of the IL‑1α/β, IL‑33, and IL‑36α/β/γ signaling pathways and contributing to the development of multiple autoimmune and inflammatory diseases. Consequently, targeting IL‑1RAP can simultaneously block several IL‑1 family inflammatory pathways, with the potential to rapidly control inflammation, alleviate gout symptoms, and allow earlier initiation of urate‑lowering therapy. Preclinical data indicate that IBI3011 can significantly suppress gout flares in models of acute gouty arthritis, underscoring the clinical potential of IBI3011. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: Innovent Biologics does not recommend the use of unapproved drugs/indications. Forward-Looking Statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. SOURCE Innovent Biologics

Phase 1Phase 2Clinical Result

21 Nov 2025

·www.biopharmadive.com

FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M

Today, a brief rundown of news from The Food and Drug Administration and Profluent, as well as updates from Novartis, Innovent Biologics and Flagship Pioneering that you may have missed.The Food and Drug Administration announced a new pilot program intended to speed up communications with drugmakers following formal meetings. The new program allows companies the opportunity after a meeting to submit an email question to agency staff asking for a quick clarification regarding a specific issue. The FDA then aims to respond within three business days. The pilot is initially being tested out through the agencys Office of New Drugs, but could eventually be expanded more widely. Numerous drug developers have told me that a quick touchpoint or clarification opportunity with the FDA team could spare them months of guesswork, said Commissioner Martin Makary, in a statement. Ben FidlerNovartis hiked the sales estimates for two of its top drugs and revealed plans this week to expand its manufacturing footprint in North Carolina. On Thursday, Novartis raised its projections for the leukemia medicine Scemblix and the breast cancer therapy Kisqali, which it now expects to peak at more than $14 billion combined annually. A day earlier, Novartis said itll build three new sites in North Carolina producing biologics, tablets, sterile packaging and more. The new plans are part of a $23 billion U.S. drug production pledge Novartis made earlier this year. Ben FidlerBezos Expeditions, the private investment office of Jeff Bezos, teamed with a group of investors to pour $106 million into AI-focused startup Profluent. In an announcement Wednesday, Profluent said itll direct the cash towards generative AI systems that can help design novel proteins that, in turn, can be used to make new drugs or better agricultural crops. Profluent's Protein Atlas has already made more than 115 billion unique proteins, which it claims is the worlds largest data resource of its kind. The startup is already worth close to $1 billion, according to a Forbes report. Ben FidlerAn experimental obesity drug Innovent Biologics is codeveloping with Eli Lilly is headed towards a regulatory submission in China. Innovent said Wednesday that the drug, which stimulates the two gut hormones GLP-1 and glucagon, met all of its main and key secondary goals in a Phase 3 trial in China, spurring as much as about 19% weight loss over 60 weeks in adults with obesity compared to 3% for placebo recipients. An approval application will be filed for the medication, called mazdutide, in the near term, the company said. Lilly and Innovent have collaborated on multiple drugs over the last several years and, in 2019, added mazdutide to their alliance. Ben FidlerFlagship Pioneering on Thursday revealed new developments related to a 2024 collaboration with GSK, announcing agreementsbetween the pharma and its startups ProFound Therapeutics and Quotient Therapeutics. ProFound will help GSK unearth treatments for chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Quotient, meanwhile, will search for drug targets for those two conditions, as well as metabolic dysfunction-associated steatohepatitis. If GSK decides to continue on, both startups will handle key preclinical activities, after which the big drugmaker will have the option to advance programs coming from the work into human testing.GSK and Flagships deal last year enabled the pharma company to dip into the venture firms portfolio of startups to find up to 10 new medicines or vaccines. Gwendolyn Wu '

Phase 3Drug ApprovalClinical Result

100 Deals associated with Mazdutide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	China	Innovent Biologics (Suzhou) Co. Ltd.	16 Sep 2025
Obesity	China	Innovent Biologics (Suzhou) Co. Ltd.	24 Jun 2025
Overweight	China	Innovent Biologics (Suzhou) Co. Ltd.	24 Jun 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	13 May 2025
Metabolic dysfunction-associated steatotic liver disease	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	22 Apr 2025
Early-onset type II diabetes	Phase 3	China	Innovent Biologics (Suzhou) Co. Ltd.	29 Feb 2024
Metabolic Dysfunction Associated Steatohepatitis	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	20 Jun 2025
Heart failure with mid range ejection fraction	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	01 Apr 2025
Heart failure with normal ejection fraction	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	01 Apr 2025
Heart failure with reduced ejection fraction	Phase 2	China	Innovent Biologics (Suzhou) Co. Ltd.	01 Apr 2025
Hypertension	IND Approval	China	Innovent Biologics (Suzhou) Co. Ltd.	20 Jan 2026
Hyperuricemia	Preclinical	China	Innovent Biologics (Suzhou) Co. Ltd.	12 Jul 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05606913 (DREAMS-2, Nature \| Pubmed \| PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	731	Mazdutide 4 mg	difwwcfgmv(vqbyllvqwz) = zkrwgrlfxh nbtzbzavnf (iolddwjxlz ) Met View more	Superior	17 Dec 2025
				Mazdutide 6 mg	difwwcfgmv(vqbyllvqwz) = tmxehojflz nbtzbzavnf (iolddwjxlz ) Met View more
NCT05628311 (DREAMS-1, Nature \| Pubmed \| PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	320	Mazdutide 4 mg	ccedkcxrbc(dwgpbusrwt) = yprrbxiebm ceqgdvcbpl (thuwkkbaul ) Met View more	Positive	17 Dec 2025
				Mazdutide 6 mg	ccedkcxrbc(dwgpbusrwt) = tdsnjjptgw ceqgdvcbpl (thuwkkbaul ) Met View more
PRNewswire Manual	Phase 1	Obesity	36	mazdutide 4 mg	ekzvbmfyvd(nlgsuenykg) = jchzlyvtfc dotvgoxwqb (tdmekuipuq ) Met View more	Positive	11 Dec 2025
				mazdutide 6 mg	ekzvbmfyvd(nlgsuenykg) = baorlbmwzt dotvgoxwqb (tdmekuipuq ) Met View more
NCT06164873 (GLORY-2, Company_Website) Manual	Phase 3	Obesity	462	Mazdutide 9 mg	uhwrlktxss(qnbzvuqfpb) = audlehkfpt agvkejrfvf (eidrjqgrni ) Met View more	Positive	20 Nov 2025
				Placebo	uhwrlktxss(qnbzvuqfpb) = nepfbqdgre agvkejrfvf (eidrjqgrni ) Met View more
NCT05623839 (Pubmed \| Diabetes Obes Metab)	Phase 1	Overweight \| Obesity	32	Mazdutide (Cohort 1)	iudsterims(zqccpctivm) = the most common AEs were mild or moderate gastrointestinal disorders. guqmacbqcn (hbmbcbiucx )	Positive	01 Nov 2025
				Mazdutide (Cohort 2)
NCT06184568 (DREAMS-3, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2	349	mazdutide 6 mg	anzkpzqwuh(nyozizlexb) = qodsitlbdo crzgrryppe (njratmzjca ) Met View more	Positive	26 Oct 2025
				semaglutide 1 mg	anzkpzqwuh(nyozizlexb) = uqdrtbpdjk crzgrryppe (njratmzjca ) Met View more
NCT05607680 (GLORY-1, Pubmed) Manual	Phase 3	Overweight \| Obesity	610	mazdutide 4mg	oqzlafljiu(bqaayuwmtp) = ruqjpwdjbq klckqhcxcx (jcqtcfzlfv, -11.15 to -9.04) View more	Positive	24 May 2025
				mazdutide 6mg	oqzlafljiu(bqaayuwmtp) = gumphnvmsz klckqhcxcx (jcqtcfzlfv, -13.64 to -11.45) View more
NCT05607680 (GLORY-1, NEWS) Manual	Phase 3	Overweight \| Obesity	610	Mazdutide	dozpenqxpi(vsraekeuxy) = oypcrpamxn rloenwjpfz (rcgoeeszxi ) View more	Positive	13 Sep 2024
				Mazdutide (4 mg)	qywvrwuwnv(pfdolkakqn) = ytqjyxgldt zrejuwiegx (bggkijvwqv ) View more
NCT05606913 (DREAMS-2, EASD2024) Manual	Phase 3	Diabetes Mellitus, Type 2	731	mazdutide 4mg	sdluhsxhct(yrgdrymysi) = nmtorhqxuz ooyrpcwjmg (koshoiodbe ) View more	Positive	11 Sep 2024
				mazdutide 6mg	sdluhsxhct(yrgdrymysi) = nuqojstvnc ooyrpcwjmg (koshoiodbe ) View more
NCT05623839 (EASD2024) Manual	Phase 1	Overweight \| Obesity	32	Mazdutide (cohort 1)	swkejrqlmb(nwrnfyddyx) = hnzrxlgnby nbbhfbnjwe (voftckfkif ) View more	Positive	09 Sep 2024
				Mazdutide (cohort 2)	swkejrqlmb(nwrnfyddyx) = zktkasxasl nbbhfbnjwe (voftckfkif ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis